Israel Active

Post Injury Epilepsy (PIE) occurs several months after a stroke in at least 10% of patients. Scientists at Ben Gurion University have been able to detect likely PIE sufferers using EEG (electroencephalographic) recordings of theta brain waves. Early treatment with medication can prevent attacks.

When Israel’s BioLineRx bought UK’s Agalimmune, it also acquired its AGI-134 treatment for solid tumors. BioLineRX has just demonstrated successful results of AGI-134 in two pre-clinical melanoma studies.

Researchers at Israel’s Bar-Ilan University have discovered a new enzyme called FerT, which exists only in the energy-generating mitochondria of cancer cells. When the enzyme was targeted in lab tests, the malignant cells were unable to produce energy and died.

I featured previously Israeli startup Zebra Medical Vision which uses Artificial Intelligence to analyze the results of medical scans. Zebra is offering all its algorithms for $1 per scan. Now all hospitals can afford to test patients for osteoporosis, cardiac disease, liver disease, early cancer etc.

I featured previously the Israeli-developed MyMDBand QR-coded wristband that provides paramedics with a patient’s vital medical data. Israeli Asaf Luxembourg, just won a WeWork Creator Award for it.  United Hatzalah have distributed thousands of MyMDBands to the elderly.

I reported previously that the minimally invasive RENOVA leg implant from Israel’s BlueWind to treat Overactive Bladder (OAB) had been granted European approval. Recent trials show that device gave over 50% improvement to 71% of participants.

I’ve reported previously on Israeli biotech Pluristem’s PLX stem cell treatment for many life-threatening conditions. Recent lab trials with modified PLX cells showed significant inhibitory effect on various lines of breast, colorectal, kidney, liver, lung, muscle and skin cancers.

I reported previously on the US takeover of Israeli biotech Kite for $12 billion. The US FDA has now approved Kite’s Yescarta treatment for adults with relapsed or refractory large B-cell lymphoma. The treatment uses Israeli-developed CAR-T therapy from the patient’s own T-cells.

Following a Priority Review, the US FDA has approved Israel TEVA’s Leukemia treatment, TRISENOX® (arsenic trioxidec). Trisenox is to be used in combination with tretinoin for treatment of recently-diagnosed low-risk adults with acute promyelocytic leukemia (APL).

Israel’s Laniado hospital used groundbreaking stem cell treatment from Israel’s BioGenCell to save amputating the legs of five diabetic patients with poor circulation. Stem cells from the patients’ blood injected into their leg muscles grew new blood vessels to bypass blockages.